RESUMO
Flucloxacillin-induced hypokalaemia can be progressive and life-threatening, despite of potassium supplementation. In this case description, a high dose of intravenous flucloxacillin was started after a 68-year-old patient presented with an infected knee replacement. After two days, hypokalaemia was noted with an inadequate response to potassium supplementation. It was decided to change antibiotics and increase potassium supplementation, with good results. It is advisable to include monitoring of potassium levels in local treatment protocols when flucloxacillin is prescribed.
Assuntos
Floxacilina , Hipopotassemia , Idoso , Humanos , Administração Intravenosa , Antibacterianos/efeitos adversos , Floxacilina/efeitos adversos , Hipopotassemia/induzido quimicamente , PotássioRESUMO
Intravenous flucloxacillin is one of the most frequently used high-dose penicillin therapies in hospitalized patients, forming the cornerstone treatment of invasive Staphylococcus aureus infection. Being a nonreabsorbable anion, flucloxacillin has been suggested to cause hypokalaemia, although the frequency and magnitude of this unwanted effect is unknown. In a retrospective cohort, we investigated the incidence and extent of hypokalaemia after initiation of intravenous flucloxacillin or ceftriaxone therapy. In total, 77 patients receiving flucloxacillin (62% male, mean age 70.5 years) and 84 patients receiving ceftriaxone (46% male, mean age 70.8 years) were included. Hypokalaemia occurred significantly more often in patients receiving flucloxacillin than ceftriaxone (42% vs 14%, p < 10-4 ). Moreover, follow-up potassium levels were significantly lower during flucloxacillin therapy. In general, women were more prone to develop hypokalaemia than men. In conclusion, intravenous flucloxacillin use is associated with a striking incidence of hypokalaemia. Therefore, standardized potassium measurements are necessary.
Assuntos
Antibacterianos/efeitos adversos , Floxacilina/efeitos adversos , Hipopotassemia/induzido quimicamente , Infecções Estafilocócicas/tratamento farmacológico , Administração Intravenosa , Idoso , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Estudos de Coortes , Feminino , Floxacilina/administração & dosagem , Floxacilina/uso terapêutico , Humanos , Hipopotassemia/epidemiologia , Incidência , Masculino , Potássio/sangue , Estudos Retrospectivos , Infecções Estafilocócicas/sangueRESUMO
OBJECTIVE AND IMPORTANCE: Flucloxacillin is a narrow-spectrum beta-lactam antibiotic with activity against penicillinase producing staphylococci and streptococci. Severe hypokalaemia is an uncommon, but serious adverse effect in patients treated with penicillin derivates. CLINICAL PRESENTATION: We report a case of severe hypokalaemia in a patient treated with high dose intravenous flucloxacillin. CONCLUSION: This case report highlights the importance of monitoring electrolytes during treatment with high dose flucloxacillin. If severe hypokalaemia is noted during treatment, this should be considered in the differential diagnosis.
Assuntos
Antibacterianos/efeitos adversos , Floxacilina/efeitos adversos , Hipopotassemia , Idoso , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Feminino , Floxacilina/administração & dosagem , Floxacilina/uso terapêutico , Humanos , Hipopotassemia/induzido quimicamente , Hipopotassemia/diagnóstico , Potássio/sangue , Infecção da Ferida Cirúrgica/tratamento farmacológicoAssuntos
Antibacterianos/efeitos adversos , Anticoagulantes/uso terapêutico , Floxacilina/efeitos adversos , Varfarina/uso terapêutico , Antibacterianos/administração & dosagem , Relação Dose-Resposta a Droga , Interações Medicamentosas , Endocardite Bacteriana/tratamento farmacológico , Floxacilina/administração & dosagem , Próteses Valvulares Cardíacas , Humanos , Coeficiente Internacional Normatizado , Masculino , Pessoa de Meia-Idade , Valva Mitral/cirurgiaRESUMO
A 55-year-old woman with psoriasis vulgaris was treated with oral 5-methoxypsoralen and UVA photochemotherapy. After 40 treatments over 3 months she became unwell with hepatitis attributable to the psoralen. Six years earlier she developed cholestatic hepatitis to flucloxacillin. A previous history of drug-induced reactions should be sought before prescribing further drugs with similar adverse effects.
Assuntos
Doença Hepática Induzida por Substâncias e Drogas/etiologia , Metoxaleno/análogos & derivados , Terapia PUVA/efeitos adversos , Psoríase/tratamento farmacológico , 5-Metoxipsoraleno , Feminino , Floxacilina/efeitos adversos , Humanos , Metoxaleno/efeitos adversos , Pessoa de Meia-Idade , Penicilinas/efeitos adversosRESUMO
Policy makers and health professionals charged with implementing policies to improve medication use require knowledge as to how to integrate and co-ordinate strategies and interventions which have been shown to be effective. Experimental methodologies are commonly used to assess the effectiveness of interventions to improve medication use and while valuable for determining the effectiveness of particular interventions, they do not add to our understanding of how to co-ordinate and integrate multiple initiatives to improve medication use. We argue that analyses of the overall system of events which are implemented to improve medication use are also needed. In this paper, we demonstrate how the case study analysed within the framework of the Transtheoretical Model of behaviour change can be used to provide an understanding of the relationship of events which result in changes in medication use. A case study of the sequence of events which led to changes in the utilisation of flucloxacillin in Australia is assessed. The analysis demonstrated that the effectiveness of individual interventions was dependent upon the initiatives which were implemented concurrently and those that had been implemented previously. Changes in the utilisation of flucloxacillin resulted from regulatory interventions and the promotion of appropriate alternative therapies. The effectiveness of this change was enhanced by previous interventions which had raised awareness amongst health professionals of the adverse hepatic reaction associated with the use of flucloxacillin. This methodology adds to those currently employed to study methods of improving use of medications. It provides an understanding of the role of each initiative in the overall system. This is valuable for policy makers, providing them with information on how to co-ordinate and orchestrate the myriad of activities which support quality use of medicines.
Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Prescrições de Medicamentos/estatística & dados numéricos , Controle de Medicamentos e Entorpecentes/organização & administração , Floxacilina/efeitos adversos , Penicilinas/efeitos adversos , Padrões de Prática Médica/estatística & dados numéricos , Austrália/epidemiologia , Cefalexina/uso terapêutico , Cefalosporinas/uso terapêutico , Doença Hepática Induzida por Substâncias e Drogas/epidemiologia , Uso de Medicamentos , Conhecimentos, Atitudes e Prática em Saúde , Pessoal de Saúde/educação , Pessoal de Saúde/psicologia , Humanos , Modelos Psicológicos , FarmacoepidemiologiaAssuntos
Humanos , Anemia Hemolítica Autoimune/etiologia , Doença Medicamentosa , Ceftriaxona/efeitos adversos , Combinação Trimetoprima e Sulfametoxazol/efeitos adversos , Floxacilina/efeitos adversos , Fluconazol/efeitos adversos , Isoniazida/efeitos adversos , Pirazinamida/efeitos adversos , Síndrome da Imunodeficiência Adquirida/complicações , Estreptomicina/efeitos adversos , Testes Imunológicos/tendênciasAssuntos
Humanos , Anemia Hemolítica Autoimune/etiologia , Doença Medicamentosa , Síndrome da Imunodeficiência Adquirida/complicações , Pirazinamida/efeitos adversos , Ceftriaxona/efeitos adversos , Combinação Trimetoprima e Sulfametoxazol/efeitos adversos , Fluconazol/efeitos adversos , Floxacilina/efeitos adversos , Estreptomicina/efeitos adversos , Isoniazida/efeitos adversos , Testes Imunológicos/tendênciasRESUMO
Drugs and other chemical toxins account for less than 5% of cases of jaundice or acute hepatitis and fewer cases of chronic liver disease, but they are an important cause of more severe types of hepatic injury. Drug reactions produce an array of hepatic lesions that mimic all known hepatobiliary diseases; this poses a diagnostic challenge for physicians and pathologists. Diagnosis of drug-induced hepatic injury is circumstantial, with positive rechallenge being the only factor that unequivocally implicates a particular agent. Nonetheless, other aspects of the temporal relationship between drug ingestion and adverse reaction, exclusion of other diseases, the presence of extrahepatic features of drug hypersensitivity and some findings on liver biopsy can lend support to the diagnosis. Some of these issues will be explored in this review by considering contemporary paradigms of drug-induced hepatic injury. Factors that predispose to dose-dependent hepatic injury will be considered in relation to acetaminophen, an example of acute hepatotoxicity, and methotrexate, an agent that can produce hepatic fibrosis. Flucloxacillin will be discussed as an example of drug-induced cholestatic hepatitis often associated with prolonged cholestasis and the vanishing bile duct syndrome. Minocycline and diclofenac will be mentioned as two drugs for which drug hepatitis is an exceedingly rare complication. Finally, the evidence that Chinese herbal medicines can be hepatotoxic will be reviewed.